PR
IMVT icon

PSP Research’s Immunovant IMVT Stock Holding History

PSP Research’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$501K Sell
13,000
-6,200
-32% -$189K 0.27% 19
2026
Q1 		$477K Sell
19,200
-1,105
-5% -$28.6K 0.34% 25
2025
Q4 		$516K Buy
+20,305
New +$453K 0.45% 70

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PSP Research's IMVT Position: Q2 2026 in Review

PSP Research reduced its Immunovant (IMVT) stake by 32% in Q2 2026, selling an estimated $189K and leaving 13,000 shares worth $501K. The position accounts for 0.27% of the portfolio, ranked #19.

PSP Research first reported a position in IMVT in Q4 2025 and has held it in 3 quarters since. The position peaked at $516K in Q4 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • PSP Research held 13,000 shares of Immunovant worth $501K as of Q2 2026.
  • PSP Research sold 6,200 Immunovant shares in Q2 2026, an estimated $189K.
  • Immunovant made up 0.27% of PSP Research's portfolio in Q2 2026, its #19 holding.
  • PSP Research first reported a position in Immunovant in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Immunovant position peaked at $516K in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.